We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Biogen Idec and Elan intend to file a supplemental biologics application (sBLA) for Tysabri in the “coming weeks” — a move the firms hope will lead to a relaunch of the withdrawn multiple sclerosis (MS) drug.